Product Code: DMKC0181187
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.recasts.
- Datamonitor Healthcare estimates that in 2016, there were approximately 615 million prevalent cases of acne worldwide, and forecasts that number to increase to 673 million prevalent cases by 2025. Approved drugs in the acne space target retinoic acid receptor, bacterial ribosome, bacterial protein synthesis, dihydropteroate synthetase, steroid 5a-reductase, estrogen receptor alpha, estrogen receptor beta, folate receptor, mineralocorticoid receptor, and progesterone receptor. These are commonly administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for acne are in Phase II. Therapies in mid-to-late-stage development for acne focus on a variety of targets. The majority of the drugs in mid-to-late-stage development for acne are administered via the topical route, with the remainder being oral, subcutaneous and intravenous.
- High impact upcoming events for drugs in the acne space include topline Phase II and Phase III trial results. There were 21 licensing and asset acquisition activities involving acne drugs during 2012-17, seven of which occurred in 2014. The $50m license agreement between Actavis (now Allergan) and Mayne Pharma, pursuant to which Actavis will divest the US rights to Doryx brand acne treatment and related assets to Mayne, was the largest deal during the 201217 period.
- Yaz's sales ranked highest among drugs available for acne during 2012-16. The clinical trials distribution across Phase I-IV indicates that the majority of trials for acne have been in late phases of development, with 55% of trials in Phase III-IV, and 45% in Phase I-III.
- The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- GlaxoSmithKline has the highest number of completed clinical trials for acne
TABLE OF CONTENTS
- Topical therapy
- Systemic therapy
- Physical treatments
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
- Galderma Pioneers NDA Path Into OTC Acne Treatment Market
- Indian Start-up Vyome Wins Milestone FDA Nod For Acne Studies
LICENSING AND ASSET ACQUISITION DEALS
- Sato licenses Japanese rights to Novan's acne candidate SB204
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
- Xenon Down On Novel Acne Treatment Failure
- Prescription information:
LIST OF FIGURES
- Figure 1: Trends in prevalent cases of acne, 2016-25
- Figure 2: Pipeline drugs for acne in the US
- Figure 3: Pipeline drugs for acne, by country
- Figure 4: Pipeline drugs for acne, by drug type
- Figure 5: Pipeline drugs for acne, by classifications
- Figure 6: Key upcoming events in acne
- Figure 7: Licensing and asset acquisition deals in acne
- Figure 8: Parent patents in acne
- Figure 9: Clinical trials in acne
- Figure 10: Top 10 drugs for clinical trials in acne
- Figure 11: Top 10 companies for clinical trials in acne
- Figure 12: Trial locations in acne
- Figure 13: Acne trials sponsors, by status
- Figure 14: Acne trials sponsors, by phase
LIST OF TABLES
- Table 1: Prevalent cases of acne, 2016-25
- Table 2: Marketed drugs for acne
- Table 3: Approvals by country for acne
- Table 4: Pipeline drugs for acne in the US
- Table 5: Historical global sales, by drug ($m), 2012-16
- Table 6: Forecasted global sales, by drug ($m), 2017-22